Chemotherapy News and Research

Latest Chemotherapy News and Research

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Wolf Medical Supply, Inc. and I-Flow Corporation, a division of Kimberly-Clark Corporation, have settled out of court ending the patent dispute regarding the Redi-Flo™ Infusion Pump.

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

The National Cancer Coalition is pleased to announce that it recently received a $25,000 grant award from the Hospira Foundation, the philanthropic arm of Hospira, Inc., to support its pharmaceutical relief program within the Dominican Republic. NCC is seeking to significantly increase the levels of medical resources that it provides to the public hospitals of the Dominican Republic in an effort to more fully treat the country's underserved patients, and this grant will contribute toward achieving that goal.

24 May 2010

State roundup: Genetic testing on campus, Texas docs in Mass., and more

"A plan by the University of California, Berkeley to voluntarily test the DNA of incoming freshman has come under fire from critics who said the school was pushing an unproven technology on impressionable students. The university has said it will send test kits to 5,500 new students to analyze genes that help control the body's responses to alcohol, dairy products and folic acid" (Wohlsen, 5/21).

24 May 2010

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.

21 May 2010

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

Competitive Technologies, Inc. today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT's Calmare Pain Therapy Treatment.

21 May 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois, as part of the ASCO proceedings.

21 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Caregivers can give complete clinical picture of brain cancer patients' condition

Despite grim prognoses and aggressive treatments, cancer patients suffering from malignant gliomas -- primary brain tumors -- often rate their quality of life more optimistically than their caregivers do, according to a new Northwestern University Feinberg School of Medicine study.

21 May 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Wolf Medical Supply, I-Flow settle patent dispute on Redi-Flo Infusion Pump

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

State roundup: Genetic testing on campus, Texas docs in Mass., and more

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

New therapy program serves as foundation for ongoing clinical development

Cancer Institute of New Jersey investigators target autophagy

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Genentech to present new data for targeted cancer medicines at 46th ASCO

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Caregivers can give complete clinical picture of brain cancer patients' condition

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in